Ultragenyx Pharmaceutical Inc. (RARE) stock
RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.73+1.03 (+6.17%)
Close on Nov 18, 2026Market cap $1.75BP/E –Yield –
Ultragenyx Pharmaceutical price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Ultragenyx Pharmaceutical's price to sales ratio was 2.3× on Nov 11, 2026, against 5.3× a year earlier. Over the last 5 years it ranged from 2.1× to 15.9×, with a median of 7.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.3× | −1.2 |
| 2025 | Dec 31, 2025 | 3.5× | −3.9 |
| 2024 | Dec 31, 2024 | 7.4× | −1.0 |
| 2023 | Dec 29, 2023 | 8.4× | −1.0 |
| 2022 | Dec 30, 2022 | 9.5× | −6.4 |
| 2021 | Dec 31, 2021 | 15.9× | −23.2 |
| 2020 | Dec 31, 2020 | 39.1× | +9.9 |
| 2019 | Dec 31, 2019 | 29.2× | −29.1 |
| 2018 | Dec 31, 2018 | 58.4× | – |
See a number that looks wrong?